Friday 6 November 2026
Export CERS’s income statement to Excel — free account
Cerus Corporation
CERS Healthcare Medical Devices
- Revenue
- +6.28%
- EPS
- −2,800.0%
- Free cash flow
- +2,471.3%
- Total debt
- −25.4%
Quarter to September 2026, against a year earlier
2.03
0.10
−4.69%
Follow CERS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.68 | 1.44 | 2.36 | 1.91 | |
P/FCF ratio |
354.35 | 0.00 | 0.00 | 971.53 | |
P/Operating CF |
63.33 | (115.89) | (220.09) | 159.61 | |
P/B ratio |
6.04 | 5.17 | 8.28 | 6.29 | |
Price to Tangible BV |
6.17 | 5.28 | 8.44 | 6.40 | |
EV/Sales |
1.68 | 1.46 | 2.40 | 1.93 | |
EV/EBITDA |
0.00 | 0.00 | 9,004.57 | 0.00 | |
EV/Operating CF |
81.38 | 135.92 | 245.88 | 139.03 | |
EV/FCF |
355.26 | (293.71) | (324.93) | 984.16 | |
Quick Ratio |
1.12 | 1.02 | 1.02 | 1.10 | |
Current Ratio |
1.73 | 1.63 | 1.83 | 1.96 | |
Net Debt/EBITDA |
(4.07) | 47.38 | (6.19) | 7.76 | |
Debt/Assets |
37.81% | 38.06% | 31.64% | 30.94% | |
Debt/Equity |
1.29 | 1.24 | 0.92 | 0.83 | |
Asset Turnover |
1.11 | 1.14 | 1.19 | 1.20 | |
Operating CF/Net income |
(2.84) | 1.86 | 0.91 | (5.47) | |
Capex/Depreciation |
(3.33) | (0.52) | (1.89) | (1.40) | |
Interest Coverage |
(0.33) | (0.19) | (1.08) | 0.31 | |
Research and Development Expense of Revenue |
25.38% | 24.26% | 22.73% | 22.29% | |
Selling, General and Administrative Expense of Revenue |
32.25% | 33.31% | 36.12% | 34.24% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
7.63% | 8.19% | 8.68% | 9.52% | |
Graham Net Nets |
0.04 | 0.06 | 0.04 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(3.89%) | (2.75%) | (1.20%) | (1.59%) | |
Free Cash Flow Yield |
0.28% | (0.34%) | (0.31%) | 0.10% | |
Revenue per Share |
0.34 | 0.31 | 0.32 | 0.32 | |
Operating CF per Share |
0.03 | (0.02) | (0.01) | 0.01 | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.03 | (0.02) | (0.02) | 0.01 | |
Cash per Share |
0.43 | 0.41 | 0.28 | 0.28 | |
Shareholders Equity per Share |
0.34 | 0.35 | 0.35 | 0.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.34 | 0.35 | 0.35 | 0.38 | |
Free Cash Flow |
4.89 | (3.28) | (3.53) | 2.42 | |
Working Capital |
73.58 | 67.96 | 71.52 | 76.56 | |
Capital Expenditures |
(1.31) | (0.23) | (0.87) | (0.59) | |
Net Current Asset Value |
17.49 | 20.72 | 22.84 | 28.20 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
30.08 | 27.83 | 31.18 | 30.17 | |
Average Payables |
24.85 | 29.73 | 32.02 | 25.57 | |
Average Inventory |
47.13 | 54.64 | 60.17 | 58.91 | |
Average Assets |
211.39 | 214.84 | 209.13 | 209.96 | |
Average Common Equity |
60.93 | 62.26 | 63.44 | 69.28 |
Columns are period end dates · fundamentals updated 6 Nov 2026